Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
Grifols S.A. ADR dominated the market today, gaining €0.40 (5.370%).
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | 5.370% | -1.258% | 4.667% | 15.441% | 3.289% | -4.268% | -49.872% |
| Beximco Pharmaceuticals Ltd. GDR | 64.580% | 64.583% | 65.272% | 84.579% | 76.339% | 50.476% | -29.464% |
| Eledon Pharmaceuticals Inc. | 3.660% | 18.056% | 25.926% | -55.959% | 32.813% | -34.109% | -85.192% |
| SELLAS Life Sciences Group Inc | 3.470% | 14.214% | 81.842% | 257.966% | 20.459% | 33.294% | -31.135% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat